Syringe
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 14/403,801, filed Nov 25, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,103,644 | Syringe In force · Low confidence | Novartis AG | In force | Low confidence | ||
| US 11,110,226 | Syringe In force · Low confidence | Novartis AG | In force | Low confidence | ||
| US 11,147,925 | Syringe In force · Medium confidence | Novartis AG | In force | Medium confidence | ||
| US 11,179,521 | Syringe In force · Low confidence | Novartis AG | In force | Low confidence | ||
| US 11,185,635 | Syringe In force · Low confidence | Novartis AG | In force | Low confidence | ||
| US 12,048,837 | Syringe In force · Low confidence | Novartis AG | In force | Low confidence | ||
| Application 14/403,801 | Syringe Abandoned Abandoned Aug 12, 2019 | Novartis AG | Abandoned | Abandoned Aug 12, 2019 | ||
| Application 17/500,174 | Syringe Abandoned Abandoned Dec 20, 2022 | Novartis AG | Abandoned | Abandoned Dec 20, 2022 | ||
| Application 18/760,445 | Syringe Pending Not granted | Novartis AG | Pending | Not granted |
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Novartis AG.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.